Exercise as a mean to control low-grade systemic inflammation

Neha Mathur, Bente Klarlund Pedersen, Neha Mathur, Bente Klarlund Pedersen

Abstract

Chronic noncommunicable diseases (CNCDs), which include cardiovascular disease, some cancers, for example, colon cancer, breast cancer, and type 2 diabetes, are reaching epidemic proportions worldwide. It has now become clear that low-grade chronic inflammation is a key player in the pathogenesis of most CNCDs. Given that regular exercise offers protection against all causes of mortality, primarily by protection against atherosclerosis and insulin resistance, we suggest that exercise may exert some of its beneficial health effects by inducing anti-inflammatory actions. Recently, IL-6 was introduced as the first myokine, defined as a cytokine, which is produced and released by contracting skeletal muscle fibres, exerting its effects in other organs of the body. We suggest that skeletal muscle is an endocrine organ and that myokines may be involved in mediating the beneficial effects against CNCDs associated with low-grade inflammation.

References

    1. Daar AS, Singer PA, Persad DL, et al. Grand challenges in chronic non-communicable diseases. Nature. 2007;450(7169):494–496.
    1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors. Global Burden of Disease and Risk Factors. Washington DC, USA: Oxford University Press and The World Bank; 2006.
    1. WHO global report. Geneva, Switzerland: World Health Organization; 2005. Preventing chronic diseases: a vital investment.
    1. Adeyi O, Smith O, Robles S. Public Policy and the Challenge of Chronic Noncommunicable Diseases. Washington DC, USA: The World Bank; 2007.
    1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874.
    1. Packard RRS, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical Chemistry. 2008;54(1):24–38.
    1. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology. 2004;25(1):4–7.
    1. Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. Journal of Applied Physiology. 2005;98(4):1154–1162.
    1. Myers J, Kaykha A, George S, et al. Fitness versus physical activity patterns in predicting mortality in men. American Journal of Medicine. 2004;117(12):912–918.
    1. Khaw KT, Wareham N, Bingham S, Welch A, Luben R, Day N. Combined impact of health behaviours and mortality in men and women: the EPIC-Norfolk prospective population study. PLoS Medicine. 2008;5(1):p. e12.
    1. Sui X, LaMonte MJ, Laditka JN, et al. Cardiorespiratory fitness and adiposity as mortality predictors in older adults. Journal of the American Medical Association. 2007;298(21):2507–2516.
    1. Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scandinavian Journal of Medicine & Science in Sports. 2006;16(supplement 1):3–63.
    1. Wilund KR. Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease? Clinical Science. 2007;112(11-12):543–555.
    1. Thune I, Furberg A-S. Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Medicine & Science in Sports & Exercise. 2001;33(supplement 6):S530–S550.
    1. Lamonte MJ, Blair SN, Church TS. Physical activity and diabetes prevention. Journal of Applied Physiology. 2005;99(3):1205–1213.
    1. Lee I-M, Paffenbarger RS, Jr., Hennekens CH. Physical activity, physical fitness and longevity. Aging. 1997;9(1-2):2–11.
    1. Pedersen BK. State of the art reviews: health benefits related to exercise in patients with chronic low-grade systemic inflammation. American Journal of Lifestyle Medicine. 2007;1(4):289–298.
    1. Pedersen BK, Steensberg A, Fischer C, et al. Searching for the exercise factor: is IL-6 a candidate? Journal of Muscle Research and Cell Motility. 2003;24(2-3):113–119.
    1. Febbraio MA, Pedersen BK. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exercise and Sport Sciences Reviews. 2005;33(3):114–119.
    1. Pedersen BK. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays in Biochemistry. 2006;42:105–117.
    1. Edwards KM, Burns VE, Carroll D, Drayson M, Ring C. The acute stress-induced immunoenhancement hypothesis. Exercise and Sport Sciences Reviews. 2007;35(3):150–155.
    1. Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. Journal of Leukocyte Biology. 2005;78(4):819–835.
    1. Zeyda M, Farmer D, Todoric J, et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. International Journal of Obesity. 2007;31(9):1420–1428.
    1. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proceedings of the Nutrition Society. 2001;60(3):349–356.
    1. Bulló M, García-Lorda P, Megias I, Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obesity Research. 2003;11(4):525–531.
    1. Gil A, María Aguilera C, Gil-Campos M, Cañete R. Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity. British Journal of Nutrition. 2007;98(supplement 1):S121–S126.
    1. Gleeson M. Immune function in sport and exercise. Journal of Applied Physiology. 2007;103(2):693–699.
    1. Pedersen BK, Fischer CP. Physiological roles of muscle-derived interleukin-6 in response to exercise. Current Opinion in Clinical Nutrition and Metabolic Care. 2007;10(3):265–271.
    1. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory process in type 2 diabetes: the role of cytokines. Annals of the New York Academy of Sciences. 2006;1084:89–117.
    1. Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, DeSouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity. 2006;14(12):2127–2131.
    1. Bennet AM, Prince JA, Fei G-Z, et al. Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. Atherosclerosis. 2003;171(2):359–367.
    1. Reilly MP, Rohatgi A, McMahon K, et al. Plasma cytokines, metabolic syndrome, and atherosclerosis in humans. Journal of Investigative Medicine. 2007;55(1):26–35.
    1. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Annals of Internal Medicine. 2006;145(1):21–29.
    1. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. The New England Journal of Medicine. 2002;347(20):1557–1565.
    1. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α . Cytokine and Growth Factor Reviews. 2003;14(5):447–455.
    1. Rydén M, Arner P. Tumour necrosis factor-α in human adipose tissue—from signalling mechanisms to clinical implications. Journal of Internal Medicine. 2007;262(4):431–438.
    1. Krogh-Madsen R, Plomgaard P, Møller K, Mittendorfer B, Pedersen BK. Influence of TNF-α and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. American Journal of Physiology. 2006;291(1):E108–E114.
    1. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867.
    1. Lee Y-H, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Current Diabetes Reports. 2005;5(1):70–75.
    1. Plomgaard P, Nielsen AR, Fischer CP, et al. Associations between insulin resistance and TNF-α in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia. 2007;50(12):2562–2571.
    1. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science. 1996;271(5249):665–668.
    1. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death and Differentiation. 2003;10(10):1165–1177.
    1. Vary TC, Deiter G, Lang CH. Diminished Erk 1/2 and p38 mapk phosphorylation in skeletal muscle during sepsis. Shock. 2004;22(6):548–554.
    1. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005;54(10):2939–2945.
    1. Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, van Hall G. Tumor necrosis factor-α modulates human in vivo lipolysis. The Journal of Clinical Endocrinology & Metabolism. 2008;93(2):543–549.
    1. Bastard J-P, Maachi M, Van Nhieu JT, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. The Journal of Clinical Endocrinology & Metabolism. 2002;87(5):2084–2089.
    1. Carey AL, Bruce CR, Sacchetti M, et al. Interleukin-6 and tumor necrosis factor-α are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia. 2004;47(6):1029–1037.
    1. Steensberg A, Fischer CP, Sacchetti M, et al. Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. The Journal of Physiology. 2003;548(2):631–638.
    1. Lyngsø D, Simonsen L, Bülow J. Interleukin-6 production in human subcutaneous abdominal adipose tissue: the effect of exercise. The Journal of Physiology. 2002;543(1):373–378.
    1. Petersen EW, Carey AL, Sacchetti M, et al. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. American Journal of Physiology. 2005;288(1):E155–E162.
    1. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. Journal of Biological Chemistry. 2003;278(46):45777–45784.
    1. Fasshauer M, Klein J, Lossner U, Paschke R. Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha, growth hormone, and IL-6 in 3T3-L1 adipocytes. Hormone and Metabolic Research. 2003;35(3):147–152.
    1. Kim H-J, Higashimori T, Park S-Y, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004;53(4):1060–1067.
    1. Wallenius V, Wallenius K, Ahrén B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nature Medicine. 2002;8(1):75–79.
    1. Glund S, Deshmukh A, Long YC, et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes. 2007;56(6):1630–1637.
    1. Carey AL, Steinberg GR, Macaulay SL, et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006;55(10):2688–2697.
    1. Al-Khalili L, Bouzakri K, Glund S, Lönnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Molecular Endocrinology. 2006;20(12):3364–3375.
    1. van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. The Journal of Clinical Endocrinology & Metabolism. 2003;88(7):3005–3010.
    1. Bruce CR, Dyck DJ. Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-α . American Journal of Physiology. 2004;287(4):E616–E621.
    1. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. The FASEB Journal. 2002;16(11):1335–1347.
    1. Pedersen BK, Hoffman-Goetz L. Exercise and the immune system: regulation, integration, and adaptation. Physiological Reviews. 2000;80(3):1055–1081.
    1. Pedersen BK, Steensberg A, Schjerling P. Exercise and interleukin-6. Current Opinion in Hematology. 2001;8(3):137–141.
    1. Pedersen BK. IL-6 signalling in exercise and disease. Biochemical Society Transactions. 2007;35, part 5:1295–1297.
    1. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Pedersen BK. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. The Journal of Physiology. 2000;529(1):237–242.
    1. Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. The Journal of Physiology. 1999;515(1):287–291.
    1. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990;75(1):40–47.
    1. Matthys P, Mitera T, Heremans H, Van Damme J, Billiau A. Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice. Infection and Immunity. 1995;63(4):1158–1164.
    1. Mizuhara H, O'Neill E, Seki N, et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. Journal of Experimental Medicine. 1994;179(5):1529–1537.
    1. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-α production in humans. The FASEB Journal. 2003;17(8):884–886.
    1. Pedersen BK, Febbraio MA. Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. Journal of Applied Physiology. 2007;102(2):814–819.
    1. Fischer CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK. Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scandinavian Journal of Medicine & Science in Sports. 2006;17(5):580–587.
    1. Halle M, Korsten-Reck U, Wolfarth B, Berg A. Low-grade systemic inflammation in overweight children: impact of physical fitness. Exercise Immunology Review. 2004;10:66–74.
    1. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. American Journal of Epidemiology. 2001;153(3):242–250.
    1. Fallon KE, Fallon SK, Boston T. The acute phase response and exercise: court and field sports. British Journal of Sports Medicine. 2001;35(3):170–173.
    1. Mattusch F, Dufaux B, Heine O, Mertens I, Rost R. Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. International Journal of Sports Medicine. 2000;21(1):21–24.
    1. Bruunsgaard H, Ladelund S, Pedersen AN, Schroll M, Jørgensen T, Pedersen BK. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clinical & Experimental Immunology. 2003;132(1):24–31.
    1. Cesari M, Penninx BWJH, Pahor M, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. Journals of Gerontology Series A. 2004;59(3):242–248.
    1. Tisi PV, Hulse M, Chulakadabba A, Gosling P, Shearman CP. Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response? European Journal of Vascular and Endovascular Surgery. 1997;14(5):344–350.
    1. Stewart LK, Flynn MG, Campbell WW, et al. The influence of exercise training on inflammatory cytokines and C-reactive protein. Medicine & Science in Sports & Exercise. 2007;39(10):1714–1719.
    1. Goldhammer E, Tanchilevitch A, Maor I, Beniamini Y, Rosenschein U, Sagiv M. Exercise training modulates cytokines activity in coronary heart disease patients. International Journal of Cardiology. 2005;100(1):93–99.
    1. Petersen AMW, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects of exercise. Journal of Physiology and Pharmacology. 2006;57(supplement 10):43–51.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera